Unformatted text preview: Substantially all of these costs were paid in 2009. The following two questions relate to this impairment. a. What is the total value of impairment related to the write-down of non-cash impaired assets with no future use? b. What is the total value of impairment related to additional severance and environmental cleanup charges related to a previously announced strategic restructuring decision? 6. How much cash was paid for capital expenditures (purchases of PPE) during 2009? 7. How much cash did Eli Lilly receive from selling/disposing of its PPE during 2009?...
View Full Document
- Spring '10
- Depreciation, Generally Accepted Accounting Principles, Eli Lilly, Eli Lilly Financial